Interview with Polarean Imaging CTO Dr. Bastiaan Driehuys on the FDA Approval of Lung Imaging Drug Device Combo Xenoview – Xtalks Life Science Podcast Ep. 97

In this week’s Xtalks Life Science podcast episode, Ayesha and the editorial team spoke with Dr. Bastiaan Driehuys, Founder and Chief Technology Officer at Polarean Imaging plc.

Polarean is a medical imaging company focused on improving the state of lung imaging that recently received FDA approval for its drug-device combination product, Xenoview. Prepared from the Xenon 129 Gas Blend, Xenoview is a hyperpolarized contrast agent indicated for use with MRI to evaluate lung ventilation in adults and pediatric patients 12 years of age and older.

Tune into the episode to learn more about the FDA approval of Xenoview, including the journey to its approval. Hear about Dr. Driehuys’ extensive research career developing hyperpolarized Xenon 129 as an MRI contrast agent and how that led him to found Polarean with the goal of improving the state of lung imaging.

Read more at: Lung Disease Diagnostic Xenoview Gets FDA Approval for Use with MRI

The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.

Subscribe to the Xtalks Life Science Podcast to never miss a new episode.